Understood - I was talking more generally about risks from drugs targeted at human proteins likely being greater than those targeted at the actual virus. Also, safety information from HIV trials may not translate well to trials on COVID patients - which is why we need to see the controlled trial results.
Sounds like Cytodyn has completed enrollment for its phase II, 75-patient randomized/controlled trial in mild to moderate COVID patients - do you know when results from that will be published? The EIND study is not controlled (it's emergency use data) - do you have a link to some paper or report on the EIND results to date? Surely you understand the skepticism given so many false claims out there on other drugs, combined with your "take my word for it" posts, which include no links to published research. Also, the phase II trial might not be statistically powered well enough (hence it only being phase II) to show definitive efficacy results, especially since most mild/moderate patients recover. Maybe the results will be great and we can all celebrate, but from my perspective I simply haven't seen much yet.
I also didn't say the drug had significant risk or was not effective, since I have no clue about either, clinically, since we haven't seen results from randomized controlled studies yet. I just said it's less likely to be safe and effective than an engineered antibody treatment which targets the virus.
https://www.biotech-capital.com/com...-to-moderate-symptoms-of-covid-19-921739.html